EHSF 2026: UCB presented long-term BE HEARD trial in patients with Hidradenitis Suppurativa

ACTRIMS 2026: Roche’s investigational therapy fenebrutinib shows breakthrough results in primary progressive multiple sclerosis (PPMS)

FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients | iPharmaCenter

Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter

From $31.60 to $25: How New PBS Rules Make Prescriptions More Affordable

CDSCO Clears Durvalumab with FLOT as New Perioperative Standard for Gastric Cancer Patients in India | iPharmaCenter

GSK’s RSV Vaccine, Arexvy is now approved for all adults in Europe | iPharmaCenter

AHA Urges HRSA to Block Eli Lilly’s Expanded 340B Claims-Data Policy; Lilly Hits Back | iPharmaCenter

Roche’s GLP‑1/GIP receptor agonist CT‑388 demonstrated strong efficacy in patients with obesity | iPharmaCenter

NHS England lowers FIT threshold to catch more bowel cancers early

NICE greenlights Dupixent as add-on therapy for uncontrolled COPD with raised eosinophils in England, marking first targeted biologic for this indication | iPharmaCenter

Amlitelimab meets primary endpoints in Phase 3 atopic dermatitis trials, enabling Sanofi regulatory submissions | iPharmaCenter

Sun Pharma obtains DCGI nod to produce generic semaglutide injection for weight management in India | iPharmaCenter

SFDA approved the registration of Anktiva for selected bladder and lung cancer indications | iPharmaCenter

CVS Health outlines strategy to streamline insurance and cut patient costs | iPharmaCenter

FDA clears one‑minute subcutaneous mosunetuzumab for heavily pretreated follicular lymphoma | iPharmaCenter

China Approves Myqorzo and Redemplo, Expanding Options in Hypertrophic Cardiomyopathy and Familial Chylomicronaemia Syndrome | iPharmaCenter

Lilly’s Sofetabart Mipitecan Wins FDA Breakthrough Tag in Tough‑to‑Treat Ovarian Cancer | iPharmaCenter

Aspect Biosystems Deepens Novo Nordisk Alliance to Advance Curative Cell Therapies for Diabetes | iPharmaCenter

Moderna and Merck report 5‑year follow‑up for intismeran autogene plus pembrolizumab in resected high‑risk melanoma | iPharmaCenter

GSK to Acquire RAPT in $2.2 Billion Deal, Adding Late-Stage Anti-IgE Candidate Ozureprubart for Food Allergy and Chronic Spontaneous Urticaria | iPharmaCenter

EMA Begins Review of Trastuzumab Deruxtecan Plus Pertuzumab as First-Line Therapy for HER2 Positive Metastatic Breast Cancer | iPharmaCenter

Novartis’ ianalumab moves a step closer to approval in Sjögren’s disease with FDA Breakthrough Therapy designation | iPharmaCenter

Germany’s Federal Ministry of Health (BMG) initiated two research funding projects to strengthen women's health | iPharmaCenter

J.P. Morgan 2026 Healthcare Conference | News | Updates | iPharmaCenter

Inside Trump’s Great Healthcare Plan: Drug Prices, Premiums, and Transparency Explained

Sun Pharma Launches UNLOXCYT in the U.S. for Advanced Cutaneous Squamous Cell Carcinoma

American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium 2026 | News | Updates | iPharmaCenter

Top-Selling Drugs of 2026 | iPharmaCenter

Germany Approves Draft Law to Strengthen Local Pharmacies (ApoVWG) | iPharmaCenter

Eli Lilly to acquire Ventyx Biosciences; will significantly strengthen immunology and neurology portfolio | iPharmaCenter

China Grants Approval to Nucala for COPD Management | iPharmaCenter

Japan approves GSK's Exdensur for asthma and chronic rhinosinusitis with nasal polyps

Enhertu approved in China for HER2‑low or HER2‑ultralow metastatic breast cancer | iPharmaCenter

European Commission grants approval to Sanofi's Wayrilz for refractory immune thrombocytopenia | iPharmaCenter

Boehringer Ingelheim Bolsters Pulmonary Fibrosis Portfolio with Jascayd Approval for Progressive Cases

FDA Clears Wegovy Pill as First Oral GLP-1 for US Weight Management

US FDA Grants Approval to Exdensur, ultra-long acting biologic for Severe Eosinophilic Asthma

GSK, Novartis, Merck, Gilead, BMS and Amgen cut US drug prices for tariff relief and massive US investment

American Society of Hematology (ASH) Annual Meeting and Exposition | ASH 2025 | Orlando, Florida | iPharmaCenter

HAS Provides Conditional Reimbursement for Pirtobrutinib and Restricted Use for Upadacitinib | iPharmaCenter

PBS Adds Zytorvi, First Funded Immunotherapy Option for Australians with Recurrent or Metastatic Nasopharyngeal Carcinoma | iPharmaCenter

FDA Clears Breyanzi as the First CAR T‑Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma in the US | iPharmaCenter

Johnson & Johnson Secures European Commission Approval for IMAAVY (Nipocalimab) to Treat Generalised Myasthenia Gravis

Sun Pharma Launches ILUMYA in India for Psoriasis Patients | iPharmaCenter

US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension

FDA Approves Jaypirca for Relapsed or Refractory CLL/SLL Previously Treated with Covalent BTK Inhibitors | iPharmaCenter

Best‑Selling Cancer Drugs 2025: Top 10 Brands, Uses and MOA | Best selling cancer drugs | 2025 | iPharmaCenter

CTAD 2025: Eisai Highlights Etalanetug Tau Reductions and LEQEMBI Protofibril Data; Merck Shares Early MK-2214, MK-1167 Results | Clinical Trials on Alzheimer's Disease 2025 | iPharmaCenter

Bristol Myers Squibb Extends Cobenfy Trial in Alzheimer’s Psychosis After DMC Recommendation | iPharmaCenter